Ratings by Morgan Stanley (Maxwell Skor)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/9/2026 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
65.01 (57.61) |
-11.38% | Details | |
| 12/23/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Cidara Therapeutics | CDTX | Downgrade | Equalweight (Overweight) |
105.99 (221.38) |
108.87% | Details | |
| 11/14/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2025 | Tscan Therapeutics Inc | TCRX | Downgrade | Equalweight (Overweight) |
1.19 (1.12) |
-5.88% | Details | |
| 10/31/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/16/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
110.64 (105.99) |
-4.2% | Details | |
| 8/20/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/13/2025 | Insmed | INSM | Downgrade | Equalweight (Overweight) |
112.89 (140.13) |
24.13% | Details | |
| 7/17/2025 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Equalweight) |
5.91 (14.34) |
142.64% | Details | |
| 7/3/2025 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
172.00 (240.65) |
39.91% | Details | |
| 7/3/2025 | Sana Biotechnology | SANA | New Coverage | Overweight (N/A) |
2.83 (3.15) |
11.31% | Details | |
| 5/8/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2025 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
43.27 (60.41) |
39.61% | Details | |
| 8/19/2024 | Invivyd Inc. | IVVD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Invivyd Inc. | IVVD | Upgrade | Overweight (Equalweight) |
4.36 (1.80) |
-58.72% | Details | |
| 12/7/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Vaccitech | VACC | Downgrade | Equalweight (Overweight) |
1.69 (5.00) |
195.86% | Details | |
| 8/15/2023 | Pharvaris B.V. | PHVS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/15/2023 | Pharvaris B.V. | PHVS | Upgrade | Overweight (Equalweight) |
18.56 (25.91) |
39.6% | Details |
